Skip to main content
. Author manuscript; available in PMC: 2014 Sep 9.
Published in final edited form as: Science. 2014 Jan 17;343(6168):309–313. doi: 10.1126/science.1248627

Fig. 2. Functional validation of Myh9 as a bona fide tumor suppressor.

Fig. 2

(A) Tumor-free survival of mice of the indicated genotype and shRNA transduction (n > 6 for each genotype, P < 0.0001). Insert shows skin lesions (arrows) on 4-month-old Myh9 shRNA–transduced TβRII-cKO mouse. (B) Myh9 knockdown results in pulmonary metastases in TβRII-cKO mice. Metastatic lesions are immunoreactive for epithelial keratin 14 and negative for myosin IIa. (C) Tumor-free survival of Myh9/TβRII inducible knockout (iKO) as well as Myh9 heterozygous/TβRII iKO and control mice (n = 6, P < 0.001, log-rank test).